AstraZeneca aims to pump up Farxiga marketing after cardio outcomes study

Now that AstraZeneca has scored its Farxiga outcomes data, it's aiming to change the game on its SGLT2 diabetes rivals. First up? Expanding its salesforce to prepare for a full-court press on physicians.